• Long-term control agent in the management of asthma.

Contraindicated in:

• Hypersensitivity
• Active liver disease or transaminases 3 times upper limit of normal.

Use Cautiously in:

• Acute attacks of asthma
• History of liver disease or alcohol consumption
• OB: Safety not established
• Lactation: Use while breastfeeding only if maternal benefit outweighs potential risk to infant
• Pedi: Children <12 yr (safety and effectiveness not established).

CV: chest pain.

Derm: pruritus.

EENT: conjunctivitis.

GI: abdominal pain, constipation, dyspepsia, flatulence, ↑ liver enzymes, nausea, vomiting.

GU: urinary tract infection, vaginitis.

MS: arthralgia, myalgia, neck pain.

Neuro: hypertonia, SUICIDAL THOUGHTS, headache, agitation, aggression, anxiety, depression, dizziness, dream abnormalities, hallucinations, insomnia, irritability, malaise, nervousness, restlessness, somnolence, tremor, weakness.

Misc: fever, lymphadenopathy.

Drug-Drug:

• ↑levels and effects of theophylline, beta blockers, propranolol, and warfarin.

Drug-Food:

• Food slows but does not alter extent of absorption.

(Generic available)

• Tablets: 600 mg;
• Extended-release tablet: 600 mg;

• PO (Adults and Children 12 yr): Immediate-release — 600 mg 4 times daily; Extended-release — 1200 mg twice daily.

Zyflo CR

• Inhibits the enzyme 5-lipoxygenase that catalyzes to formation of leukotrienes. Leukotrienes are components of slow-reacting substance of anaphylaxis and mediate the following:
  • Airway edema,
  • Smooth muscle constriction,
  • Altered cellular activity.
• Result is decreased inflammatory process that is part of asthma.

• Decreased incidence and severity of asthma.

Therapeutic Classification: bronchodilators

Pharmacologic Classification: leukotriene antagonists

Absorption: Rapidly absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 93%.

Metabolism/Excretion: Mostly metabolized by the liver.

Half-life: 2.5 hr.

(improvement in pulmonary function)

• Instruct patient to take medication as directed, at evenly spaced intervals, even if not experiencing symptoms of asthma. If a dose of extended release product is missed, omit and take next dose at scheduled time. Do not double doses. Do not discontinue therapy without consulting health care professional.
• Instruct patient not to discontinue or reduce other asthma medications without consulting health care professional. Health care professional should be notified if more short-acting bronchodilators than usual or more than the maximum number for 24 hr of inhalations of short-acting bronchodilator are needed.
• Advise patient that zileuton is not used to treat acute asthma attacks but may be continued during an acute exacerbation.
• Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.
• Instruct patient to notify health care professional immediately if upper right quadrant pain, nausea, fatigue, lethargy, pruritus, jaundice, or flu-like symptoms occur.
• Advise patient to notify health care professional of behavioral changes or thoughts of suicide.
• Rep: Advise to notify health care professional if pregnancy is planned or suspected and to avoid breastfeeding during therapy. Encourage patients who become pregnant during therapy to enroll in the pregnancy registry that monitors pregnancy outcomes in women exposed to asthma medications during pregnancy. For more information, contact the MothersToBaby Pregnancy Studies conducted by the Organization of Teratology Information Specialists at 1- 877-311-8972 or visit mothertobaby.org/pregnancy-studies/.

zye-LOO-ton

NDC Code^*

• 10122- Chiesi USA, Inc.
  • 10122-901- ZYFLO
    • 10122-901-12- 120 TABLET in 1 BOTTLE (10122-901-12)

• 10122- Chiesi USA, Inc.
  • 10122-902- ZYFLO CR
    • 10122-902-12- 120 TABLET, MULTILAYER, EXTENDED RELEASE in 1 BOTTLE (10122-902-12)

• 10122- Chiesi USA, Inc.
  • 10122-902- ZYFLO CR
    • 10122-902-20- 20 TABLET, MULTILAYER, EXTENDED RELEASE in 1 BOTTLE (10122-902-20)

• 64980- Rising Pharmaceuticals, Inc.
  • 64980-206- Zileuton
    • 64980-206-12- 120 TABLET, EXTENDED RELEASE in 1 BOTTLE (64980-206-12)

• 66993- Prasco, LLC
  • 66993-485- Zileuton
    • 66993-485-32- 120 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (66993-485-32)